It is generally known that the approach to managing DKD entails regulating hyperglycemia, dyslipidemia, blood pressure, and the use of renin-angiotensin-aldosterone system (RAAS) inhibitors in the early stages of DKD and more recently, sodium glucose co-transporter-2 (SGLT-2) inhibitors, glucagon-like peptide (GLP)-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) [86,87]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.